Breast Cancer Drug Resistance: Precision Targeting of ER and HER2 Signalling Networks

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Breast cancer (BC) poses a significant clinical challenge due to acquired drug resistance.
• Resistance limits treatment efficacy and negatively impacts patient survival.
• Estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) signaling pathways are critical in BC progression and treatment response.

Purpose of the Study:

• To elucidate the mechanisms of drug resistance in breast cancer.
• To investigate the roles of ER and HER2 signaling pathways in mediating resistance.
• To identify advanced therapeutic strategies to overcome resistance.

Main Methods:

• Comprehensive review of clinical data and cell line studies with known resistance profiles.
• Utilized high-throughput sequencing, proteomics, and advanced imaging techniques.
• Bioinformatic and statistical analyses of receptor expression, pathway activation, and drug response data.

Main Results:

• Identified specific mutations and alterations in ER and HER2 pathways contributing to drug resistance.
• Highlighted novel biomarkers and resistance mechanisms, including alternative signaling cascades and downstream effector mutations.
• Preclinical models showed promising results for targeted therapies like combination treatments and next-generation inhibitors.

Conclusions:

• Drug resistance in breast cancer is complex, with ER and HER2 pathways playing pivotal roles.
• Unique resistance mechanisms and potential therapeutic targets have been identified.
• Findings pave the way for developing advanced strategies to improve breast cancer treatment outcomes.